Nature Communications (Aug 2018)
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
- Christopher W. Helsen,
- Joanne A. Hammill,
- Vivian W. C. Lau,
- Kenneth A. Mwawasi,
- Arya Afsahi,
- Ksenia Bezverbnaya,
- Lisa Newhook,
- Danielle L. Hayes,
- Craig Aarts,
- Bojana Bojovic,
- Galina F. Denisova,
- Jacek M. Kwiecien,
- Ian Brain,
- Heather Derocher,
- Katy Milne,
- Brad H. Nelson,
- Jonathan L. Bramson
Affiliations
- Christopher W. Helsen
- Department of Pathology and Molecular Medicine, McMaster University
- Joanne A. Hammill
- Department of Pathology and Molecular Medicine, McMaster University
- Vivian W. C. Lau
- Department of Pathology and Molecular Medicine, McMaster University
- Kenneth A. Mwawasi
- Department of Pathology and Molecular Medicine, McMaster University
- Arya Afsahi
- Department of Pathology and Molecular Medicine, McMaster University
- Ksenia Bezverbnaya
- Department of Pathology and Molecular Medicine, McMaster University
- Lisa Newhook
- Department of Pathology and Molecular Medicine, McMaster University
- Danielle L. Hayes
- Department of Pathology and Molecular Medicine, McMaster University
- Craig Aarts
- Department of Pathology and Molecular Medicine, McMaster University
- Bojana Bojovic
- Department of Pathology and Molecular Medicine, McMaster University
- Galina F. Denisova
- Department of Pathology and Molecular Medicine, McMaster University
- Jacek M. Kwiecien
- Department of Pathology and Molecular Medicine, McMaster University
- Ian Brain
- Department of Pathology and Molecular Medicine, McMaster University
- Heather Derocher
- Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency
- Katy Milne
- Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency
- Brad H. Nelson
- Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency
- Jonathan L. Bramson
- Department of Pathology and Molecular Medicine, McMaster University
- DOI
- https://doi.org/10.1038/s41467-018-05395-y
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
Chimeric antigen receptors (CARs) are effective tools for directing T cell killing of tumors, but may cause adverse side effects. Here the authors show that coupling of antigen-recognition and CD3-binding in a modular format induces more efficient anti-tumour responses but reduced toxicity when compared with current CARs.
